Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease

Gaurav Gupta; Rajiv Dahiya; Yogendra Singh; Anurag Mishra; Aseem Verma; Sunil Kumar Gothwal; Alaa A A Aljabali; Harish Dureja; Parteek Prasher; Poonam Negi; Deepak N Kapoor; Rohit Goyal; Murtaza M Tambuwala; Dinesh K Chellappan; Kamal Dua

doi:10.1016/j.cbi.2020.108975

Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease

Chem Biol Interact. 2020 Feb 1:317:108975. doi: 10.1016/j.cbi.2020.108975. Epub 2020 Feb 4.

Authors

Gaurav Gupta¹, Rajiv Dahiya², Yogendra Singh³, Anurag Mishra⁴, Aseem Verma⁵, Sunil Kumar Gothwal⁶, Alaa A A Aljabali⁷, Harish Dureja⁸, Parteek Prasher⁹, Poonam Negi¹⁰, Deepak N Kapoor¹⁰, Rohit Goyal¹⁰, Murtaza M Tambuwala¹¹, Dinesh K Chellappan¹², Kamal Dua¹³

Affiliations

¹ School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India. Electronic address: [email protected].
² Laboratory of Peptide Research and Development, School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad & Tobago, West Indies.
³ Mahatma Gandhi College of Pharmaceutical Sciences, Sitapura, Jaipur, India. Electronic address: [email protected].
⁴ School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India.
⁵ Mahatma Gandhi College of Pharmaceutical Sciences, Sitapura, Jaipur, India.
⁶ Department of Medicine, JLN Medical College, Ajmer, India.
⁷ Faculty of Pharmacy, Department of Pharmaceutical Sciences, Yarmouk University, Irbid, 21163, Jordan.
⁸ Department of Pharmaceutical Sciences, Maharishi Dayanand University, Rohtak, Haryana, 124001, India.
⁹ Department of Chemistry, University of Petroleum & Energy Studies, Dehradun, 248007, India.
¹⁰ School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173229, India.
¹¹ School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, County, Londonderry, BT52 1SA, Northern Ireland, United Kingdom.
¹² Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia.
¹³ Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW, 2308, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia.

PMID: 32032593
DOI: 10.1016/j.cbi.2020.108975

Abstract

In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.

Keywords: Aldosterone synthase; Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; Chronic kidney disease; Hyperkalemia; Renin-angiotensin-aldosterone system.

Publication types

Review

MeSH terms

Adrenal Cortex Hormones / biosynthesis
Aldosterone / metabolism*
Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Humans
Kidney Diseases / drug therapy*
Kidney Diseases / metabolism*
Renin-Angiotensin System / drug effects*

Substances

Adrenal Cortex Hormones
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Aldosterone